Debating Interchangeability, Efficacy, and Safety of Biosimilars in the Management of Inflammatory Diseases

Biosimilars offer a potential solution as a cost-effective alternative to biologic agents to treat a variety of conditions. The first biosimilar approved in the United States to treat inflammatory diseases was the monoclonal antibody, infliximab-dyyb, which was approved in April of 2016 and followed by three additional biosimilar approvals. In this recording of a live CMEO Q&A session, Dr. Leonard Calabrese answers questions from participants while offering evidence, guidelines, and quality measures for collaborative strategies to optimally use biosimilars in patients with inflammatory diseases.